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Abstract
Background: Advances in the high-throughput omic technologies have made it possible to profile cells in a large number
of ways at the DNA, RNA, protein, chromosomal, functional, and pharmacological levels. A persistent problem is that
some classes of molecular data are labeled with gene identifiers, others with transcript or protein identifiers, and still
others with chromosomal locations. What has lagged behind is the ability to integrate the resulting data to uncover
complex relationships and patterns. Those issues are reflected in full form by molecular profile data on the panel of 60
diverse human cancer cell lines (the NCI-60) used since 1990 by the U.S. National Cancer Institute to screen compounds
for anticancer activity. To our knowledge, CellMiner is the first online database resource for integration of the diverse
molecular types of NCI-60 and related meta data.
Description: CellMiner enables scientists to perform advanced querying of molecular information on NCI-60 (and
additional types) through a single web interface. CellMiner is a freely available tool that organizes and stores raw and
normalized data that represent multiple types of molecular characterizations at the DNA, RNA, protein, and
pharmacological levels. Annotations for each project, along with associated metadata on the samples and datasets, are
stored in a MySQL database and linked to the molecular profile data. Data can be queried and downloaded along with
comprehensive information on experimental and analytic methods for each data set. A Data Intersection tool allows
selection of a list of genes (proteins) in common between two or more data sets and outputs the data for those genes
(proteins) in the respective sets. In addition to its role as an integrative resource for the NCI-60, the CellMiner package
also serves as a shell for incorporation of molecular profile data on other cell or tissue sample types.
Conclusion: CellMiner is a relational database tool for storing, querying, integrating, and downloading molecular profile
data on the NCI-60 and other cancer cell types. More broadly, it provides a template to use in providing such functionality
for other molecular profile data generated by academic institutions, public projects, or the private sector. CellMiner is
available online at http://discover.nci.nih.gov/cellminer/.
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Background
Microarrays and other new high-throughput technologies
of the past decade have made it possible to generate large
molecular profile databases on clinical cancers and cul-
tured cancer cells. Novel molecular subtypes of cancer
(differing, for example, in mechanism of transformation,
propensity to metastasize, and sensitivity to particular
therapies) have been identified from such profiles [1]. The
most value, however, can be realized by integrating the
various types of data. A number of concrete, biomedically
interesting examples have supported the 'integromic
hypothesis': i.e., that multiple types of molecular profiles
on the same set of biological samples can be synergistic
when combined [2-6]. To aid in the assembly, organiza-
tion, integration, and querying of multiple molecular pro-
file data sets on the same samples, we have developed
CellMiner, a freely available, user-friendly, web-based
resource. CellMiner currently focuses on two cancer cell
line sets, the NCI-60 and the Du145/RC.01 pair.
The NCI-60 is a panel of 60 human cancer cell lines used
by the Developmental Therapeutics Program (DTP) of the
U.S. National Cancer Institute to screen > 100,000 com-
pounds plus natural products since 1990 [7-10]. The NCI-
60 panel includes cancers of colorectal, renal, ovarian,
prostate, lung, breast, and central nervous system origin,
as well as leukemias and melanomas. We and our many
collaborators around the world have profiled the NCI-60
more comprehensively at the DNA, RNA, protein, muta-
tion, functional, and pharmacological levels than any
other set of cells in existence. The resulting data have been
the subject of a large number of integromic analyses
[5,6,10-12]. The limitations of cell lines as surrogates for
clinical tumors are well known, but an advantage of the
NCI-60 panel is the wealth of pharmacological data based
on exposure of the cells to large numbers of drugs and
other chemical compounds. Other advantages are that the
cells can be obtained in unlimited amounts, that they are
homogeneous in lineage, and that they can be manipu-
lated easily (e.g., by gene transfer or RNA interference
technologies). The information from them complements
what is available from animal and clinical studies. The
extensive profiling of the NCI-60 has been viewed as a
forerunner of The Cancer Genome Atlas project, which is
confined to a smaller set of characteristics (all of them at
the nucleic acid level) but in the more difficult context of
clinical cancers.
The NCI-60 data have been widely used in cancer research
and bioinformatics [10], but the full utility of the multiple
data sets is evident only when one integrates them to for-
mulate complex 'biosignatures' or to understand the
behaviour of pathways and systems within the cell.
CellMiner provides bioinformatic 'glue' that binds the
various data sets together and make them fluently interop-
erable. It complements database developments by the
NCI, DTP but with a particular emphasis on data queries
and integration of different molecular data types. It incor-
porates both raw and processed data, as well as metadata
on cells, experiments, and platforms. It therefore provides
the casual user with the resources needed to analyze rela-
tionships among cell and data types without going
through the often-painful task of pre-processing the data.
For example, data pre-processed using the MAS5, RMA,
and GCRMA algorithms are provided for the Affymetrix
U95 and U133 chip-sets. The user can input a list of genes,
chromosome locations, whole-genome locations, or plat-
form-specific identifiers to query or download the rele-
vant data or identify the intersection of multiple data sets.
For those who want to dig deeper or check the quality of
data for particular genes, cells, or tested compounds,
CellMiner provides the raw data (e.g., Affymetrix CEL
files). It also provides connections between the experi-
mental data and key attributes of the genes, including all
associated Genbank accession numbers, Refseq accession
numbers, chromosome numbers, and chromosomal loca-
tions. Similarly, the drug database includes NSC
(National Service Center) numbers, CIS (Chemical Infor-
mation System) numbers, and chemical structure infor-
mation whenever possible. CellMiner currently
incorporates 15 data sets, and more are being added on a
continuing basis.
Construction and content
Implementation
CellMiner is a web application that provides molecular
profile data and query tools for the NCI-60 and additional
cell types. Development of CellMiner was motivated by
the need for an intuitive, uncomplicated, streamlined tool
that integrates the various molecular data sets generated
by the Genomics & Bioinformatics Group, LMP, CCR,
NCI and its many collaborators. The application includes
metadata on experimental studies that generated the data
sets, metadata on the samples, tools for downloading the
data, tools for querying them, and a tool for finding their
intersections. CellMiner is written in JavaScript and inter-
acts with a MySQL relational database http://
www.mysql.com to save data into tables and make que-
ries related to that data. It is currently deployed on an
Apache HTTP server in the Genomics & Bioinformatics
Group http://discover.nci.nih.gov/cellminer.
Local data repositories
Essential to CellMiner are the four data repositories
shown as "Associated data" in Figure 1: (i) "Database of
Entrez Gene", the database that stores annotation infor-
mation from National Center for Biotechnology Informa-
tion (NCBI) dump files, (ii) "Database of highthroughput
arrays", which contains molecular profile data, (iii)
"Database of cell line metadata", which contains pheno-
typic metadata on the cell lines, and (iv) "Database of
dataset metadata", which contains platform-associatedBMC Genomics 2009, 10:277 http://www.biomedcentral.com/1471-2164/10/277
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Table 1: Description of the datasets included in the current version of CellMiner. More will be added on a continuing basis.
S.no Data set Description Reference
DNA
1 aCGH DNA copy number changes from bacterial artificial 
chromosome array
Bussey et al., 2006[5]
2 Mutation DNA sequencing data on mutations on 24 human 
cancer genes
Ikediobi et al, 2006[20]
3 Methylation of E-cadherin promoter PCR amplification and sequencing of sodium bisulfite 
modified DNA
Reinhold et al, 2007[22]
RNA
4 cDNA cDNA clone microarray with 9,607 features Scherf et al, 2000; Shankavaram et al., 
2007[6,12]
5 HU6800 Affymetrix 6,800-feature microarray Shankavaram et al., 2007[6]
6 HGU95 Affymetrix 64,000-feature microarray Shankavaram et al., 2007[6]
7 HGU133 Affymetrix 44,000-feature microarray Shankavaram et al., 2007[6]
8 ABC transporter RT-PCR data on 47 ABC transporters Szakacs, et al., 2004[15]
9 Ion transporter 632-feature 70-mer oligo microarray Huang et al., 2004[23]
10 NCI-60 radiation Microarray with 612 ESTs plus another set of 616 
ESTs chosen on the basis of their known roles in 
cancer lymphoid biology
Amundson et al., 2008[24]
11 microRNA 627 human microRNA probes, including 321 mature 
microRNAs, as well as probes for most of their 
precursors.
Blower et al., 2007[25]
Protein
12 RPLA Reverse phase antibody lysate array with detection 
using 156 monoclonal antibodies
Nishizuka et al, 2003; Shankavaram et al., 
2007[6,14]
Drug
13 A118 The "mechanism of action" set with 6 compound 
classes. The list of compounds was assembled for an 
earlier study as training set for neural network 
analysis of drug mechanism of action.
Weinstein et al., 1992 [18]
14 A1429 Combination of A118 and A1400 selected from > 
70,000 tested, publicly available compounds by 
applying a series of filters (see text for description)
Scherf et al., 2000; Szakacs et al., 
2004[12,15]
15 A4463 Selected compounds tested in the NCI DTP's 
sulforhodamine B assay two or more times and for 
which structure records are available.
Blower et al., 2002[19]BMC Genomics 2009, 10:277 http://www.biomedcentral.com/1471-2164/10/277
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information. Special care was taken to generate a struc-
tured layout that enables efficient queries for integration
and easy navigation of phenotypic data, metadata, and
molecular profile information for any of the platforms
and for any gene(s) of interest. As listed in Table 1, to date
CellMiner (version 1.2) includes transcript expression
data from four whole-genome microarray platforms[6,12]
and a PCR platform focused on ABC transporters[13],
protein expression data from reverse phase lysate (pro-
teomic) arrays[14], re-sequencing (mutation) data on
essentially all exons and exon splice junctions of 24 can-
cer-related genes[15], DNA copy number data from array
comparative genomic hybridization studies[5], methyla-
tion of ECAD gene promoter region[16], and drug screen-
ing data on the NCI-60 cell panel[12,13,17,18]. There is
also a link to Skyweb http://www.ncbi.nlm.nih.gov/sky/,
which organizes information from spectral karyotyping of
the NCI-60 [19]. To ensure that gene annotations are con-
sistent with the human reference sequence (RefSeq), we
used the NCBI genome assembly database (build 36) to
determine HUGO names, alias gene symbols, chromo-
some locations, protein and gene reference sequence
identifiers, and genomic sequence location. To facilitate
multiplatform comparison, for each of the high through-
put arrays in CellMiner, we have used the vendor-supplied
annotations corresponding to gene symbols and stored
them along with array data in a MySQL table. Those iden-
tifiers are, in turn, used to map NCBI assembly annota-
tions using the gene symbol as the common identifier that
connects array information to any of the gene-related
annotations.
Job execution and display of results
Based on settings selected by the user, CellMiner generates
the necessary input files and triggers execution as a back-
ground job. Depending on the query and user-selected
Schematic representation of CellMiner Figure 1
Schematic representation of CellMiner. CellMiner was constructed using four data resources (associated data). The user 
submits a job to CellMiner via a user-friendly web interface, and the job is then processed in background. Upon completion, 
results are returned to the user in a new HTML page or can be exported to various formats. CellMiner is publicly available at 
http://discover.nci.nih.gov/cellminer.BMC Genomics 2009, 10:277 http://www.biomedcentral.com/1471-2164/10/277
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options, the results can be downloaded, as shown in Table
2, as zip-compressed files (for raw data), text, MS Excel
files, or HTML (the latter displayed online in a new
browser window). For each individual job, based on out-
put options selected by user, the gene- and chromosome-
specific information is obtained from the local NCBI
Gene database. Such information is then combined with
platform-specific expression data.
Utility and discussion
The setup of the query is defined according to the param-
eters selected by the user (Table 2). Example scenarios for
each function are described below.
CellMiner metadata
CellMiner provides information on the cell lines com-
piled from multiple sources, primarily the published liter-
ature. That information forms the basis for queries that
join molecular profile data with annotations from the
gene tables. Each cell line is described, insofar as the infor-
mation is available, by standard name, cancer type, infor-
mation on the patient (anonymized), origin of the cells,
chromosomal ploidy, doubling time in culture, and muta-
tion status with respect to cancer genes of interest (e.g.,
p53 and MDR1). The user can choose to access data for
the complete NCI-60 panel, a tissue-of-origin sub panel,
or the DU145/RC01 prostate cancer pair if available.
Results are displayed as an HTML page in a new browser
Table 2: Summary of search functions and criteria available in the CellMiner resource.
Meta data Download Query Intersection Drug data Mutation data
Raw Normalized
Cell lines NCI-60/
DU145-RC0.1/
both
NCI-60/DU145/
RC0.1
NCI-60/DU145/
RC0.1
NCI-60/DU145/
RC0.1/both
NCI-60/DU145/
RC0.1
NCI-60 NCI-60 
(59 cell lines)
Dataset 
selection 
(molecular 
type)
NA DNA/RNA/
Protein
DNA/RNA/
Protein
DNA/RNA 
Protein
DNA/RNA/
Protein
Drug sensitivity DNA
User select 
cell line 
criteria
All/tissue type 
selection
All All/tissue type 
selection
All All All/tissue type 
selection
NA
User select 
identifier type
NA Raw Normalized gene or 
platform 
specific id, 
chromosome or 
genomic 
location
NA NSC, Chemical 
name, 
Molecular 
formula
NA
User select 
identifier list
NA NA NA File attachment, 
list, single value
NA File attachment, 
list, single value
NA
Output data 
fields
Information on 
Patient, cell line, 
Experimental 
details
Quantification 
of image files
Log base2 HUGO, Entrez 
Gene id, Gene 
Symbol, 
Chromosome, 
Cytoband, 
mRNA-Refseq, 
Protein-Refseq, 
Transcription 
start and 
Transcription-
end
HUGO, Entrez 
Gene id, Gene 
Symbol, 
Chromosome, 
Cytoband, 
mRNA-Refseq, 
Protein-Refseq, 
Transcription 
start and 
Transcription-
end
Chemical name, 
SMILES, 
molecular 
formula, 
molecular 
weight, 
mechanism of 
action
HUGO, 
Zygosity, CDS 
mutation, AA 
mutation, 
mutation 
characterization
Output 
Format
HTML table of 
cell line 
information
zip Text of log2 
intensity values
HTML, MS-
Excel, text file 
of log2 intensity 
values
Text file of log2 
intensity values 
for each the 
matching 
datasets
HTML, MS-
Excel, Text
HTML, TextBMC Genomics 2009, 10:277 http://www.biomedcentral.com/1471-2164/10/277
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window that can be saved as HTML or text (Figure 2). The
resulting tables can be entered directly into a spreadsheet
program such as Excel. However, caution is required
whenever gene names are entered into Excel because the
spreadsheet interprets some gene names as if they were
dates and transmogrifies them irreversibly. For example,
the cancer-related gene DEC-1 becomes 1-DEC. In all, we
have found 30 common gene names that are altered irre-
versibly in that way. We previously provided a script that
searches input files to detect and avoid those possible mis-
identifications [20].
Data download
CellMiner provides both raw and normalized data to
download. The raw data are stored in a repository as com-
pressed files of the appropriate type. For example, Affyme-
trix arrays are stored as probe-level CEL files, which can be
downloaded as zip compressed files onto local comput-
ers.
Normalized data sets were obtained by applying appropri-
ate statistical methods to the raw data, using pre-process-
ing procedures described in CellMiner in the data set
metadata section. The exact form of the data depends on
the type. For example, transcript expression levels were
log2-transformed to provide a convenient basis for queries
and for integration with other data types. The choice of
log-transformation was dictated by the distributional
properties and error structures of most hybridization-
based expression data sets. The main sample table, which
is linked to the gene annotation table, holds the unique
identifier for each data set in the repository. Results are
obtained as downloadable text files. The results page pro-
vides the experiment name, gene symbol for each probe
identifier, and log2 expression data for all of the cell lines
or cell lines selected by the user.
Dataset metadata
The user can access detailed information on the project
that produced a data set. Included are entries on the
microarray (or other technology) platform and collabora-
tors, as well as a link to the primary publication(s). A file
containing a description of the data set and the normali-
zation procedure in publication-level detail is also
included for each data set download.
Querying data sets
The search tool performs queries ranging from simple
(e.g., obtaining data from a single platform with minimal
annotation) to complex (e.g., obtaining data limited to
Illustrative screen shot of the CellMiner graphical user interface Figure 2
Illustrative screen shot of the CellMiner graphical user interface. Shown is the result of a "Cell Line Metadata" query 
on a user-selected CNS tissue subset. Included in the output are literature citations for information on the lines selected. The 
default selection is the entire NCI-60. The results shown here resulted from background processing of the job and display via 
the graphical web interface.BMC Genomics 2009, 10:277 http://www.biomedcentral.com/1471-2164/10/277
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Screen shot of the "Query Datasets" input page Figure 3
Screen shot of the "Query Datasets" input page. Shown is the result of a "Query Datasets" on a user-selected query 
options available to extract molecular profile data from CellMiner.BMC Genomics 2009, 10:277 http://www.biomedcentral.com/1471-2164/10/277
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particular platforms, with list of gene- or chromosome-
specific annotations). The search capability enables both
biologists and data analysts to retrieve data sets with spe-
cific characteristics (e.g. profiling studies at the DNA,
RNA, or protein level). The CellMiner query option allows
the user to:
1. Retrieve entire experiments as the result of complex
queries (as shown in Figure 3).
2. Retrieve particular subsets of data as the result of
more complex queries (e.g., a collection of data for a
gene of interest across multiple platforms, as illus-
trated in Figure 4).
3. Retrieve data in HTML, tab-delimited, or Microsoft
Excel format for storage in a local database or for anal-
yses on the user's computer.
CellMiner data search is performed in two steps. First, the
user selects input criteria and second, output options from
an extensive list of possibilities provided (Figure 3).
Download requests are processed in the background, and
when they are complete, a link to the requested data files
is provided in a new browser window.
Data intersection
We and our collaborators have used the cell line data in a
number of biological and pharmacological contexts. To
cite recent examples, we have used the data (i) to identify
drugs ("MDR1-inverse") that, paradoxically, are more
potent in cell that express the multi-drug resistance gene
MDR1 [13], (ii) to identify possible molecular target rela-
tionships for the drug Aminoflavone [21], and (iii) to
identify asparagines synthetase expression as a potential
biomarker for use of the enzyme-drug L-asparaginase for
treatment of ovarian or other solid tumors [12,22]. Ear-
lier, global analysis of the pharmacological data provided
information critical to the go-no go decision for clinical
development of oxaliplatin, now a standard agent for
treatment of primary and recurrent colorectal cancer. To
maximize the utility and value of the data by providing a
framework for data integration, it is critical to identify
subsets of genes for which information is available at the
DNA, RNA and protein level. The intersection resource of
CellMiner finds the genes (proteins) that are common to
two or more datasets and outputs the data for those genes
(proteins) in the respective sets.
Querying drug data
All public drug data from the NCI-60 screen are available
at the DTP website http://dtp.nci.nih.gov/. In CellMiner,
we currently include three smaller, curated sets presented
as the negative log2 of the 50% growth inhibitory concen-
tration (GI50). Those datasets have been used frequently
in publications by the Genomics & Bioinformatics Group,
as well as by other laboratories: (i) A118: the so-called
"mechanism of action" compounds. This data set was
assembled for an earlier study in which mechanisms of
action were predicted using neural networks [18]; (ii)
A1429: a 1429-compound combination of the A118 set
and additional compounds selected from the DTP's over-
all database of publicly available compounds by applying
a series of quality-control filters [12]. Selection was based
on the number of times a compound had been tested, the
number of missing values, and the number of cell lines for
which GI50 values fell within the range of concentrations
tested; (iii) A4444: chemically defined, tested compounds
with known 2D structures [17]. The curated data sets were
included in CellMiner to associate patterns of potency in
the screen with molecular structures of the compounds
and molecular characteristics of the cells.
Screen shot of the "Query Datasets" result page Figure 4
Screen shot of the "Query Datasets" result page. An illustrative output page displaying results of a complex "Query 
Datasets" search. For this particular output, the query was constructed for TP53 (identified by HUGO name) to include two 
datasets containing Gene symbols and chromosome numbers.BMC Genomics 2009, 10:277 http://www.biomedcentral.com/1471-2164/10/277
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The query page for drug data is similar to that for a gene
query in terms of input and output. For a drug data query,
the user first selects a compound data set and a tissue type
(or all cells), then submits a list of compounds in terms of
any of the following identifiers: NSC number, chemical
name, molecular formula, or a molecular weight range
(specified as low: high). The following options can be
specified for inclusion in the output: chemical name, Sim-
plified Molecular Input Line Entry Specification (SMILES)
representation, molecular formula, molecular weight,
and/or mechanism of action of the compound if availa-
ble. The output can be in any of the available format types
(i.e., HTML, text, or Excel). Download requests are proc-
essed in the background. When the download is com-
plete, a link to the requested data files is provided in a new
browser window.
Query mutation data
Because mutation data differ in format from expression
data, they are queried in CellMiner from a different menu.
The mutation data on almost all exons and exon-intron
splice junctions of 24 cancer-related genes were obtained
by re-sequencing, in collaboration with researchers at the
Wellcome Trust Sanger Institute http://www.sanger.ac.uk/
[15]. For those studies, PCR primers were designed to
amplify the exons and flanking intronic sequences of 24
cancer genes.
Conclusion
A variety of database tools are currently available to facil-
itate the integration of multiple datasets on cell lines.
Oncomine [23] and GeneX [24] are two such user-friendly
tools for storage and analysis of datasets collected from
the literature or submitted by individual users. However,
those tools do not support open-source architecture and
are limited to gene expression data.
Cell line collections are made available in resources like
the American Tissue Cell Culture (ATCC) http://
www.atcc.org, European Collection of Cell Cultures
(ECACC) http://www.hpacultures.org.uk/collections/
ecacc.jsp and European Searchable Tumour Line Database
(ESTDAB) [25]. The ATCC and ECACC databases are large
collection of cell lines and metadata associated with them.
ESTDAB is an open-source, online collection of immuno-
logically characterized tumour cell in a database that
holds deep information on immunological markers but is
limited largely to melanoma cancer cells lines. Those
resources are very different from CellMiner in that they
lack the molecular profiling data on the cell lines.
CellMiner provides a data integration resource that
includes multiple data types, platforms and cell lines from
nine diverse cancer types.
Cell Miner is an evolving application that provides a one-
stop resource for molecular and pharmacological profile
data on the widely studied NCI-60 cancer cell panel. Also
included currently (in part to provide a template for inclu-
sion of data on cell types beyond the NCI-60) are prostate
line DU145 and its topoisomerase 1-resistant derivative
RC0.1. Apart from providing a wide selection of queries
for integrating expression data with gene annotations,
CellMiner offers metadata on the cell lines, the profiling
platforms, and the profile data sets. CellMiner is thus a
practical resource that provides a data repository, query
capability, and assistance in data integration. It is tuned to
systems-oriented, integromic analyses, as well as to query-
ing of particular molecules or cell types. A frequent appli-
cation of the latter type arises from the scenario in which
the user wants to find a cell type (or cell types) with par-
ticular molecular features (e.g., p53 mutation, PTEN wild-
type, MDR1-expressing) as the basis for classical hypothe-
sis-driven experiments (e.g., siRNA knock-down, onco-
gene transfection, pharmacological sensitivity). To
enhance the utility of CellMiner, we are continuing to add
new features and databases beyond those currently
included.
Availability and requirements
Project name: CellMiner, a repository for raw and pre-
processed molecular data and a query tool for the NCI-60
cancer cell panel (and other cell types).
Project home page: http://discover.nci.nih.gov/cellminer/
Operating system: (Solaris 9 OS, supporting Apache,
MySQL, and JavaScript)
Programming language: JavaScript
Other server-side requirements: MySQL, Apache HTTP
server
License: none
Restrictions to use: none
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